Sign In
Buy FOLD
$14.49
+0 (+0%)
At Close: Jun 03, 2026
Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025
07:00am, Monday, 21'st Apr 2025
PRINCETON, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, May 1, 2025, at
4 Healthcare Stocks to Buy as the Sector Faces Government Heat
09:25am, Thursday, 17'th Apr 2025
Buy healthcare stocks like WGS, THC, RIGL and ENSG for steady returns as the focus shifts to the Trump administration's healthcare policies.
5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025
02:25pm, Monday, 07'th Apr 2025
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and soli
PHILADELPHIA, April 07, 2025 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Amicus Therapeutics, Inc. (NASDAQ: FOLD) (“Amicus”) on behalf of the company's long-term investo
New Strong Buy Stocks for April 1st
07:55am, Tuesday, 01'st Apr 2025
AFRM, TKOMY, FOLD, MASS and VFC have been added to the Zacks Rank #1 (Strong Buy) List on April 1, 2025.
Amicus Therapeutics (FOLD) Up 0.1% Since Last Earnings Report: Can It Continue?
12:36pm, Friday, 21'st Mar 2025
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock?
Amicus Therapeutics Is Very Attractive At Current Prices (Rating Upgrade)
10:21am, Monday, 17'th Mar 2025
Amicus Therapeutics, Inc., with two approved rare disease therapies, shows strong revenue growth and market potential despite a 30% stock decline since 2021. Galafold and Pombiliti+Opfolda are driving
In NCLA Amicus Win, D.C. Circuit Recognizes President Trump's Right to Fire Principal Officer
04:31pm, Thursday, 06'th Mar 2025
Hampton Dellinger v. Scott Bessent, Secretary of the Treasury, et al. Hampton Dellinger v. Scott Bessent, Secretary of the Treasury, et al.
NCLA Amicus Brief Asks Fifth Circuit to Maintain Block Against Corporate Transparency Act
02:04pm, Monday, 03'rd Mar 2025
Texas Top Cop Shop, Inc., et al. v. Pamela Bondi, Attorney General of the United States, et al. Texas Top Cop Shop, Inc., et al. v. Pamela Bondi, Attorney General of the United States, et al.
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025
07:00am, Thursday, 27'th Feb 2025
PRINCETON, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences i
FOLD's Q4 Earnings Miss, Higher Product Sales Drive Revenue Growth
11:40am, Thursday, 20'th Feb 2025
Amicus' fourth-quarter 2024 earnings miss estimates while revenues beat the same.
Compared to Estimates, Amicus Therapeutics (FOLD) Q4 Earnings: A Look at Key Metrics
10:36am, Thursday, 20'th Feb 2025
Although the revenue and EPS for Amicus Therapeutics (FOLD) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare wi
PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law LLC announces that it is investigating Amicus Therapeutics, Inc. (NASDAQ: FOLD) (“Amicus”) on behalf of the company's shareholders. Click here for additi
Amicus Therapeutics, Inc. (FOLD) Q4 2024 Earnings Call Transcript
02:04pm, Wednesday, 19'th Feb 2025
Amicus Therapeutics, Inc. (NASDAQ:FOLD ) Q4 2024 Earnings Conference Call February 19, 2025 8:30 AM ET Company Participants Andrew Faughnan - Vice President, Investor Relations Bradley Campbell - Pres
Amicus Therapeutics (FOLD) Q4 Earnings and Revenues Miss Estimates
09:30am, Wednesday, 19'th Feb 2025
Amicus Therapeutics (FOLD) came out with quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.10 per share. This compares to loss of $0.11 per share a year ago.
